NewAmsterdam Pharma (NAMS) Change in Acquisitions & Divestments (2025 - 2026)
NewAmsterdam Pharma (NAMS) posted Change in Acquisitions & Divestments of $51.0 million for Q1 2026, up 0.99% sequentially from $50.5 million in Q4 2025, and up 308.0% YoY from $12.5 million in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Change in Acquisitions & Divestments (2025 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Change in Acquisitions & Divestments for 2 years, with the latest figure at $51.0 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments rose 308.0% year-over-year to $51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.6 million (changed N/A YoY) and the FY2025 annual result came in at $122.1 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments climbed to $51.0 million in Q1 2026 per NAMS's latest filing, from $50.5 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $51.0 million in Q1 2026 and troughed at $12.5 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.50 Mn |
| Mar 31, 2026 | 51.00 Mn |
| Dec 31, 2025 | 50.50 Mn |
| Sep 30, 2025 | 34.40 Mn |
| Jun 30, 2025 | 24.66 Mn |
| Mar 31, 2025 | 12.50 Mn |